Navigation Links
MicroPhage Closes Latest Financing

LONGMONT, Colo., Nov. 20 /PRNewswire/ -- MicroPhage, Inc.,, today announced it has concluded its latest round of financing, which brings total capital raised to $11 million. Investors in this round were a combination of existing and new investors. All funds to date have come from private investors.

MicroPhage will apply proceeds of its financing to complete the validation and launch preparation of their initial diagnostic products, which address the growing need for simple, rapid and highly accurate tests for hospital-acquired infections (HAIs), such as MRSA.

R. Gary Mesch, chairman of MicroPhage commented "MicroPhage investors are confident the company will deliver badly needed diagnostic tools in the fight against MRSA and other HAIs. Closing a significant funding round in this tough financial climate is a noteworthy achievement."

MicroPhage CEO Steve Lundy added: "We have been validating our products in the field and have received excellent feedback from laboratory professionals who tested them against current methods. We are looking forward to completing our validation work and launching products, which leverage the tremendous power of bacteriophage amplification technology for rapid bacterial identification and susceptibility testing."

About MicroPhage

Based in Longmont, Colo. and privately held, MicroPhage, Inc. is working to be a global leader in developing rapid diagnostics products for bacterial identification and antibiotic susceptibility/resistance testing. Using its bacteriophage-based amplification platform, the company has developed a patented process that is a product platform or engine for rapid, easy-to-use, inexpensive diagnostic tests. Its first products, expected in late 2009, will set a new standard for clinicians in MRSA identification and antibiotic susceptibility testing, and are designed to fit the demands of hospitals and laboratories of all sizes. For further information, go to

SOURCE MicroPhage, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
2. CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate
3. Starfish Ventures Closes Australias Largest Venture Capital Fund With $185 Million Tech Fund
4. Valor Medical Closes $1.4 Million Convertible Debt and Receives ISO 13485 Certification
5. Great Basin Scientific, Inc. Closes $3.9 Million in Equity Funding
6. Micromet Closes $40 Million Private Equity Placement
7. Helix Biopharma Closes $11.4 Million Private Placement
8. ForteBio, Inc. Closes $25 Million In Series C Financing
9. AMDL, Inc. Closes Private Placement of Convertible Notes
10. World Leader in Bench-Top Flow Chemistry Instruments ThalesNano, Inc. Closes Funding Round
11. Pathwork Diagnostics Closes $20M Financing
Post Your Comments:
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT . ... a corporate overview. th Annual Oppenheimer Healthcare Conference ... a.m. PT . Jim Mazzola , vice president of ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
(Date:10/23/2015)... , Oct. 23, 2015 Research and ... the "Global Voice Recognition Biometrics Market 2015-2019" ... --> The global voice recognition biometrics ... 2014-2019. --> --> ... has been prepared based on an in-depth market analysis ...
Breaking Biology News(10 mins):